LIM/14 - Laboratório de Investigação em Patologia Hepática

O Laboratório de Investigação em Patologia Hepática é ligado ao Departamento de Patologia da Faculdade de Medicina da Universidade de São Paulo (FMUSP).

Linhas de pesquisa: patologia hepática, com ênfase na patogênese da evolução para formas mais graves de cirrose e para carcinoma hepatocelular; caracterização de anticorpos para estudos imuno-histoquímicos com ênfase em neoplasias digestivas, ginecológicas e condições obstétricas, neuropatologia.

Site oficial: http://limhc.fm.usp.br/portal/lim14-laboratorio-de-investigacao-em-patologia-hepatica/

Browse

Recent Submissions

  1. Clinical and Prognostic Impact of the Warburg Effect in Esophageal Carcinoma: Monocarboxylate Transporters as Candidates for Therapeutic Targeting

    PATHOBIOLOGY, v.90, n.4, p.251-269, 2023

    Introduction: Esophageal cancer (EC) seems to display increased glycolytic activity, but clinical studies on the expression/prognostic significance of glycometabolism-related proteins, as well as functional assays, are missing. Methods: Expression of 10 glycolytic biomarkers was evaluated by immu...

  2. Diaphragmatic hernia repair porcine model to compare the performance of biodegradable membranes against Gore-Tex®

    PEDIATRIC SURGERY INTERNATIONAL, v.40, n.1, article ID 7, 12p, 2023

    Background: Patch repair of congenital diaphragmatic hernia (CDH) using Gore-Tex (R) is associated with infection, adhesions, hernia recurrence, long-term musculoskeletal sequels and poor tissue regeneration. To overcome these limitations, the performance of two novel biodegradable membranes was ...

  3. Exosomes modified with anti-MEK1 siRNA lead to an effective silencing of triple negative breast cancer cells

    BIOMATERIALS ADVANCES, v.154, article ID 213643, 13p, 2023

    Triple negative breast cancer (TNBC) is a highly heterogenous disease not sensitive to endocrine or HER2 therapy and standardized treatment regimens are still missing. Therefore, development of novel TNBC treatment approaches is of utmost relevance. Herein, the potential of MAPK/ERK downregulatio...

  4. Gellan gum spongy-like hydrogel-based dual antibiotic therapy for infected diabetic wounds

    BIOENGINEERING & TRANSLATIONAL MEDICINE, v.8, n.3, 2023

    Diabetic foot infection (DFI) is an important cause of morbidity and mortality. Antibiotics are fundamental for treating DFI, although bacterial biofilm formation and associated pathophysiology can reduce their effectiveness. Additionally, antibiotics are often associated with adverse reactions. ...

  5. Understanding yellow fever-associated myocardial injury: an autopsy study

    EBIOMEDICINE, v.96, article ID 104810, 15p, 2023

    Background Yellow fever (YF) is a viral hemorrhagic fever, endemic in parts of South America and Africa. There is scarce evidence about the pathogenesis of the myocardial injury. The objective of this study is to evaluate the cardiac pathology in fatal cases of YF.Methods This retrospective autop...

  6. Implementation of an organized colorectal cancer screening program through quantitative fecal immunochemical test followed by colonoscopy in an urban low-income community: Guidance and strategies

    CLINICS, v.78, article ID 100278, 7p, 2023

    Fecal Immunochemical Test (FIT) followed by a colonoscopy is an efficacious strategy to improve the adenoma detection rate and Colorectal Cancer (CRC). There is no organized national screening program for CRC in Brazil. The aim of this research was to describe the implementation of an organized s...

  7. Treatment Outcomes in Patients with Advanced Fibrolamellar Hepatocellular Carcinoma Under Systemic Treatment: Analysis of Clinical Characteristics, Management, and Radiomics

    JOURNAL OF HEPATOCELLULAR CARCINOMA, v.10, p.1923-1933, 2023

    Purpose: Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare primary liver malignancy often diagnosed at advanced stages. While there are limited data on the efficacy of specific agents, we aim to report outcomes of patients treated with systemic therapies and explore prognostic factors.Pati...

  8. P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH-related HCC

    JOURNAL OF MOLECULAR HISTOLOGY, v.54, n.5, p.473-488, 2023

    The efficacy of systemic therapy for hepatocellular carcinoma (HCC) related to non-alcoholic steatohepatitis (NASH) is poorly understood. In this study we evaluated the effects of sorafenib based on the expression of molecular markers related to major hepatocarcinogenesis pathways and angiogenesi...

  9. Up-Front ASCT Overcomes the Survival Benefit Provided by HDAC-Based Induction Regimens in Mantle Cell Lymphoma: Data from a Real-Life and Long-Term Cohort

    CANCERS, v.15, n.19, article ID 4759, 25p, 2023

    Simple Summary This study aimed to assess clinical outcomes, determine survival predictors, and compare responses between different primary therapeutic modalities in a large real-world cohort of patients with mantle cell lymphoma (MCL), with a focus on assessing the impact of intensified immunoch...

  10. Nonviral Infections

    Alves, V. A. F.; Abdalla, E.. Nonviral Infections. In: . Practical Hepatic Pathology: A Diagnostic Approach A Volume in the Pattern Recognition Series, Expert Consult: Online and Print: ELSEVIER, 2011. p.253-272.